CLAIM AMENDMENTS

1. (Currently Amended) A tissue-generating product comprising a plasma matrix, one or more growth factors, at least one phospholipid and a protein scaffold for the generation of said tissue wherein the protein scaffold is a matrix of collagen, reticuline and/or elastine fibers or ~~their precursors~~ a precursor thereof.

2. (Currently Amended) The tissue-generating product ~~ace~~ according to claim 1, wherein the precursor is ~~the~~ tropocollagen or ~~the~~ tropoelastine.

3. (Currently Amended) The tissue-generating product according to claim 1 ~~or 2~~, wherein the plasma matrix is a coagulated matrix of platelet poor plasma comprising a platelet concentration lower than 500,000, 100,000 or 50,000 platelets per microlitre of the matrix forming agents.

4. (Currently Ameneded) The tissue-generating product according to claim 1, ~~any of the preceding claims,~~ wherein the growth factor is selected from the group consisting of the human (recombinant) tissue factor (rhTF), the human (recombinant) platelet-derived growth factor (rhPDGF), the human (recombinant) transforming growth factor (rhTGF), the human (recombinant) insulin-like growth factor (rhIGF), the human (recombinant) epidermal growth factor (rhEG), and ~~or~~ the human (recombinant) hepatocyte growth factor (rhHGF).

5. (Currently Amended) The tissue-generating product according to claim 1, ~~any of the preceding claims~~ which further comprises at least one buffer and at least one antibiotic.

6. (Currently Amended) The ~~tissue generating~~ tissue-generating product according to ~~any of the preceding claims,~~ claim 1, wherein the tissue is skin or an epithelial tissue of the stomach.

7. (Currently Amended) A kit for the preparation of a ~~tissue-generating~~ tissue-generating product according to claim 1, ~~any of the preceding claims,~~ which contains a vial containing human growth factors, the protein scaffold ~~elements (which are~~ element being selected from the group consisting of collagen, reticuline and/or elastine fibers ~~or~~ and their ~~precursors)~~ precursors or two distinct vials, a first containing one or more growth factors, while the second vial containing a protein scaffold ~~elements~~ element selected from ~~a~~ the group consisting of collagen, reticuline, and/or elastine fibers or their precursors, and ~~possibly~~ optionally a last vial which may contain at least one buffered agent and at least one antibiotic.

8. (Currently Amended) A method for the preparation of a ~~tissue-generating~~ tissue-generating product according to claim 1, ~~any of the claims 1 to 6,~~ in which:
- a substantially homogenous mixture is formed by mixing a plasma matrix with an effective amount of a protein scaffold ~~elements selecting~~ element selected from the group consisting of collagen, reticuline and/or elastine fibers ~~or~~ and their precursors;
- a growth factor and at least one phopholipid are added and mixed to the mixture of the protein scaffold ~~elements~~ element and the plasma matrix, and
- ~~the~~ said mixture is kept under conditions for ensuring the coagulation of the plasma matrix and the formation of the ~~tissue-generating~~ tissue-generating product.

9. (Currently Amended) The method according to claim 8, wherein the coagulation of the matrix ~~in~~ is carried out in the presence of oxygen and substantially without stirring.

10. (Currently Amended) The method according to claim 8 ~~or 9~~, wherein the coagulation is carried out at a temperature comprised between 35° and 40° C~~, more preferably at a temperature of about 37°C~~.

11. (Canceled)

12. (Currently Amended) A method for generating a tissue in a mammal patient, including ~~the humans~~ a human, in need thereof, said method comprising the step of applying at the place where the tissue has to be generated the ~~generating~~ tissue-generating product according to claim 1 ~~any of the claims 1 to 6~~.

13. (New) A method for treating tissue damage in a mammal patient, including human, comprising administering to the patient the tissue-generating product of claim 1.

14. (New) The tissue-generating product according to claim 2, wherein the plasma matrix is a coagulated matrix of platelet poor plasma comprising a platelet concentration lower than 500,000, 100,000 or 50,000 platelets per microlitre of the matrix forming agents.

15. (New) The tissue-generating product according to claim 2, wherein the growth factor is selected from the group consisting of the human (recombinant) tissue factor (rhTF), the human (recombinant) platelet-derived growth factor (rhPDGF), the human (recombinant) transforming growth factor (rhTGF), the human (recombinant) insulin-like growth factor (rhIGF), the human (recombinant) epidermal growth factor (rhEG), and the human (recombinant) hepatocyte growth factor (rhHGF).

16. (New) The tissue-generating product according to claim 2, which further comprises at least one buffer and at least one antibiotic.

17. (New) The tissue-generating product according to claim 2, wherein the tissue is skin or an epithelial tissue of the stomach.

18. (New) A method for the preparation of a tissue-generating product according to claim 2, in which:

- a substantially homogenous mixture is formed by mixing a plasma matrix with an effective amount of a protein scaffold element selected from the group consisting of collagen, reticuline and/or elastine fibers and their precursors;
- a growth factor and at least one phopholipid are added and mixed to the mixture of the protein scaffold element and the plasma matrix, and
- said mixture is kept under conditions for ensuring the coagulation of the plasma matrix and the formation of the tissue-generating product.

19. (New) The method according to claim 18, wherein the coagulation of the matrix is carried out in the presence of oxygen and substantially without stirring.

20. (New) The method of claim 8, wherein the coagulation is carried out at a temperature of about 37°C.

21. (New) The method of claim 9, wherein the coagulation is carried out at a temperature of about 37°C.